Sleep, Social Anxiety Disorder
Conditions
Brief summary
With this study, the investigators aim to use sleep and dreaming in order to enhance exposure therapy for social anxiety disorder (SAD), by pairing the positive feedback phase of exposure (public talk) to an auditory stimulus during wake (associated sound) and subsequently applying this stimulus during sleep (targeted memory reactivation, TMR). Exposure therapy sessions will take place in a virtual reality (VR) environment, while physiological measures during the preparation phase of public talk such as heart rate variability (HRV), skin conductance response (SCR) and subjective level of anxiety (SUDS) will be used in order to assess treatment efficiency across the sessions. Patients with SAD according to DSM-5 criteria will be included. The main hypothesis of this study is that participants who are presented with the associated sound during sleep (TMR group) will have reduced intensity of social anxiety compared to participants with no such association (control group), after both a full night's sleep with auditory stimulation during REM sleep in the laboratory, and after 1 week of stimulation during REM sleep at home. In addition, it is expected that fear-related dreams may correlate with anxiety levels during wakefulness after 1 week of stimulation at home.
Interventions
BEHAVIORALExposure Therapy and Targeted memory reactivation during REM sleep
Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound is associated with a waking experience (i.e., positive feedback in this study) and strengthening it during REM sleep, the investigators aim to accelerate the remission of social anxiety disorder.
BEHAVIORALExposure Therapy
These patients will receive the classic treatment of Exposure Therapy (ET) for social anxiety disorder without any association with a sound.
Sponsors
University Hospital, Geneva
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
16 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* Patients with social anxiety disorder (according to DSM-5 criteria and Liebowitz Social Anxiety Scale \> 65) * aged between 16 and 40 yo * no current treatment for SAD (cognitive-behavioral therapy, medications)
Exclusion criteria
* mood disorder, psychosis,other anxiety disorder or other mental disorders according to DSM-5 criteria * sleep disorder (e.g.,insomnia disorder, obstructive sleep apnea syndrome, restless legs syndrome) according to DSM-5 criteria * use of psychiatric medication * current treatment for SAD (cognitive-behavioral therapy, medications) * neurological disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Root mean square of the successive [R-R intervals] differences | 1 day | The RMSSD is used to estimate the vagally mediated changes in heart rate variability. |
| Subjective Units of Distress Scale | 1 day | Validated rating of subjective distress on a scale of 0 to 10 (higher values reflect a worse outcome) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Non-specific skin conductance responses | 1 day | The skin conductance response measures sympathetic nervous system activation. |
| Change of fear in dreams (average of fear during the second week with stimulations minus the first week without stimulations) | 1 week | Use of a dream diary where the emotion of fear is graded in a dichotomous way (presence/absence). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Liebowitz Social Anxiety Scale | 3 months | Validated self-report measure used to assess degree of social anxiety on a scale of 0 to 144 (higher values reflect a worse outcome) |
Countries
Switzerland
Outcome results
None listed